Real-World Data Collection of GORE Devices Used In the Endovascular Treatment of Aortic Aneurysms Which Incorporate Visceral Arteries.
Key facts
- Where
- Amsterdam and Tilburg, NetherlandsSee the 2 sites
Where in Netherlands
- Amsterdam UMCAmsterdam, NetherlandsNo longer taking part
- Elisabeth-TweeSteden HospitalTilburg, NetherlandsNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- W.L.Gore & Associates
- Trial code
- NCT07480395
- Record updated
- 23 October 2026
- Original description
The registry population consists of patients presenting with complex aortic pathologies amenable to endovascular aortic repair that requires the incorporation of bridging stents to maintain visceral artery perfusionRead full original descriptionShow less
The ENVISION Registry: REal-World Data CollectioN of GORE deVIceS Used In the endOvascular treatmeNt of Aortic Aneurysms Which Incorporate Visceral Arteries.
The registry population consists of patients presenting with complex aortic pathologies amenable to endovascular aortic repair that requires the incorporation of bridging stents to maintain visceral artery perfusion
Inclusion: Informed Consent Form (ICF) is signed by Subject; Age ≥ 18 years at time of informed consent signature; Patient presents with thoracoabdominal, pararenal, juxtarenal, or short-neck infrarenal aortic pathology suitable for endovascular repair; Patient requires the incorporation of ≥ 1 visceral artery and is suitable for use of at least 1 GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (BXB) as a bridging stent (Note: Up to six (6) visceral arteries may be incorporated); Patient is willing to adhere to the institutional standard of care follow-up.
Exclusion: Patient has a prior visceral artery stenting not associated with registry procedure; Patient is intended to be treated with a parallel grafting (e.g., chimney, periscope, sandwich) or octopus technique; Known hypersensitivity to heparin or a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II; Patient has known coagulation disorders including hypercoagulability that are not amenable to treatment; Patient treated for acute or sub-acute dissection, <90 days from onset of symptoms; Patient has a life expectancy < 1-year; Patient is participating in an investigational study which may confound registry results, unless approved by Gore.